412 related articles for article (PubMed ID: 32370758)
1. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
2. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N
J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935
[TBL] [Abstract][Full Text] [Related]
3. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
4. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
Pokhrel R; Chapagain P; Siltberg-Liberles J
J Med Microbiol; 2020 Jun; 69(6):864-873. PubMed ID: 32469301
[No Abstract] [Full Text] [Related]
5. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: Rescue by transcriptional inhibition.
Shilatifard A
Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
[No Abstract] [Full Text] [Related]
7. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
9. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
10. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
[TBL] [Abstract][Full Text] [Related]
11. HIV and SARS-CoV-2: points to consider to face this new pandemic.
Prieto Pozo AA; Salvador Sagüez FLD
Medwave; 2020 Oct; 20(9):e8049. PubMed ID: 33141814
[TBL] [Abstract][Full Text] [Related]
12. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
13. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
14. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
15. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Elfiky AA
Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Ju J; Li X; Kumar S; Jockusch S; Chien M; Tao C; Morozova I; Kalachikov S; Kirchdoerfer RN; Russo JJ
Pharmacol Res Perspect; 2020 Dec; 8(6):e00674. PubMed ID: 33124786
[TBL] [Abstract][Full Text] [Related]
17. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
18. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
F1000Res; 2020; 9():1166. PubMed ID: 33204411
[No Abstract] [Full Text] [Related]
19. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
Konkolova E; Dejmek M; Hřebabecký H; Šála M; Böserle J; Nencka R; Boura E
Antiviral Res; 2020 Oct; 182():104899. PubMed ID: 32763313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
